Botox for migraine: continuing a noble tradition
This article was originally published in Scrip
Executive Summary
Last week, the UK Medicines and Healthcare products Regulatory Agency (MHRA) licensed Allergan’s Botox (botulinum toxin type A) for use as a preventive treatment in patients with chronic migraine. The granting of the licence is not only the first approval worldwide of Botox in this indication (a US sBLA for chronic daily headache/migraine was filed last year), but also represents the first prophylactic treatment to receive a specific licence for patients with chronic migraine.